The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response
Williams J1, Lucarelli N2, Nicoll A1,2, Lubel J1,2. Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.
Author information
1 Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.
2 Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
Abstract
There are limited real-world data on the efficacy of direct acting antiviral (DAA) therapy for hepatitis C (HCV) in Australia. In this study, the efficacy of DAA therapy for HCV was compared between cirrhotic and non-cirrhotic cohorts. Patients without end-of-treatment response (EoTR) were observed to ascertain likelihood of achieving sustained virological response at 12 weeks post-treatment (SVR12). A total of 334 patients with HCV was included. Overall SVR12 was 96.7% with minimal differences in SVR12 between the cirrhosis and non-cirrhosis groups (95.7 and 97.3%). There were 20 patients (5.99%) that failed to achieve an EoTR of which 80.0% (n = 16) went on to achieve SVR12. These results suggest DAA therapy is effective with high rates of SVR12 even in patients that do not achieve an EoTR.